Furthermore, new treatment options targeting estrogen signaling by selective ERβ agonists, thereby avoiding ERα effects, or by treatment with estrogen receptor modulators such as tamoxifen, which acts as an ERβ agonist on DLBCL, may be applied in the future [19]. Here, ESR2 is linked to diffuse large B-cell lymphoma.